Tag: biologics
Future Biosimilars: Upcoming Patent Expirations and Market Entry
Biosimilars are set to transform healthcare as major biologics like Keytruda and Eylea lose patent protection between 2025 and 2030. With billions in savings on the line, how will the U.S. market respond?
Read More